Our Story

Elliott Dunn

Analyst - Dunedin

Elliott joined Brandon Capital in 2020.

Prior to joining Brandon Capital, Elliott project managed the research team at Blis Technologies Ltd. Previously, Elliott was a Commercialisation Analyst for Otago Innovation Ltd and a Scientific Officer in pharmacology at the University of Otago.

After completing his PhD in 2018, Elliott chaired the Return On Science Biotech & Pharma and Otago Momentum Investment Committees, established two Government funded student-led investment committees in New Zealand, and conducted research for Upside Biotechnologies Ltd, which focused on developing a bioengineered solution for burns victims.

Elliott is a board observer of Amaroq Therapeutics, and a director of Cadmus Animal Health and TamoRx.

Elliott has a PhD in Stem Cell Biology from the University of Auckland, and a Bachelor and Masters in Immunology from the University of Otago. He is currently an active committee member of the Return on Science Biotech & Pharma and Otago Momentum Investment Committees.

Brandon Capital is aware of scammers impersonating us - offering jobs and asking for bank details. We do not offer employment or ask for banking details via SMS, websites or phone calls. Do not provide any details and report to the relevant authorities in your location.